Patients suffering from
headache, particularly
migraine type, are among the most dissatisfied patients. The aim of this study was comparing the efficacy of
pregabalin with
valproate sodium, in preventing
migraine headache. In a randomized, double-blinded study, adult patients eligible for prophylactic treatment (i.e., patients with 4-15 attacks per month in last two months) were recruited. Patients' demographic data, duration of symptoms,
headache frequency (attacks per month) and intensity (based on visual analogue scale) and also drugs used to relief
headache were recorded. The patients were randomly assigned to two groups;
valproate sodium (200 mg two times daily) and
pregabalin (50 mg two times daily). The patients were examined by neurology specialist monthly for three months and the related data were recorded. The Data were analyzed using SPSS version 21, with related statistical tests. Total number of 140 patients with recurrent
migraine were entered into the study. Sixty-nine patients were assigned to group A and 71 to group B by the randomizing table. Inter-group analysis of data in two arms of the study showed that two medications were equally effective except that
pregabalin was not significantly effective in reducing number of attacks during first month of
therapy compared to baseline. This differences were not significant at second and third month of the study. Our study showed that
pregabalin, has comparable efficacy with
valproate sodium in reducing
migraine frequency, intensity, and duration of attacks and could be an alternative for
migraine prophylaxis.